医学
肝细胞癌
辅助治疗
佐剂
阶段(地层学)
切除术
烧蚀
米兰标准
射频消融术
外科
门静脉
肿瘤科
内科学
癌症
肝移植
移植
古生物学
生物
标识
DOI:10.1016/j.jceh.2024.101360
摘要
Currently, there is no standard adjuvant therapy for patients with early-stage hepatocellular carcinoma (HCC) following potentially curative resection or ablation treatment. The recently published IMbrave050 study1 addresses the pressing issue of providing effective adjuvant treatment for HCC patients following curative-intent resection or ablation with a high risk of tumor recurrence. For resection, the criteria for assessing a high recurrence risk included factors such as tumor size, tumor number, microvascular invasion, segmental portal vein invasion (Vp1 or Vp2), poorly differentiated histology, or a combination of these factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI